Cannabinoids in rehabilitation medicine: From controversy to clinical potential

For many years, cannabinoids have been regarded less as a scientific therapeutic option and more within the context of social stigma, political debate, and legal restrictions.However, contemporary neuroscience and clinical research increasingly indicate that this perspective is gradually changing.[1,2] Today, the central question in rehabilitation medicine is no longer whether cannabinoids should be discussed, but rather how these agents can be integrated in a safe, rational, and evidence-based manner to support functional recovery in chronic neurological conditions requiring longterm rehabilitation, such as multiple sclerosis (MS), spinal cord injury, stroke, cerebral palsy, and traumatic brain injury (TBI).The success of rehabilitation is not defined solely by pain reduction but by improvements in mobility, activities of daily living, social participation, and overall quality of life.Two key considerations emerge in this context.First, whether cannabinoids can support patients' engagement in rehabilitation beyond providing symptomatic relief warrants direct investigation.Second, this potential role must be weighed against current uncertainties in clinical practice and important safety concerns.